Skip to main content
Triangle logo TriangleGet started

Amivantamab (NCT06667076)

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): a one-minute explainerNCT066670761 min

Amivantamab trial for Carcinoma, Non-Small-Cell Lung (NCT06667076). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with incurable advanced or metastatic non-small-cell lung cancer carrying an EGFR exon-19 deletion or L858R mutation.

The idea: give amivantamab under the skin with oral lazertinib as first treatment, or with carboplatin and pemetrexed infusions as second treatment. Amivantamab targets EGFR and MET growth signals; lazertinib blocks mutant EGFR. The groups use four-week or three-week cycles without randomization. Researchers assess how long patients live without cancer progression. Treatment continues until progression or other stopping criteria.

This phase 2 study plans 480 patients. Janssen sponsors 119 recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.